+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global HIV Vaccines Market by Antibodies (Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment), Type (Acute Paronychia, Candidal Paronychia, Chronic Paronychia), Category - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5533222
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The HIV Vaccines Market size was estimated at USD 677.83 million in 2023, USD 943.11 million in 2024, and is expected to grow at a CAGR of 39.62% to reach USD 7,011.84 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HIV Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HIV Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc., Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline plc, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Novartis AG, Oncolys Biopharma, Profectus Biosciences, Sanofi SA, and TVAX Biomedical.

Market Segmentation & Coverage

This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Antibodies
    • Dicloxacillin
    • Fusidic Acid Ointment
    • Gentamicin Ointment
    • Mupirocin Ointment
  • Type
    • Acute Paronychia
    • Candidal Paronychia
    • Chronic Paronychia
    • Pyogenic Paronychia
  • Category
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the HIV Vaccines Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the HIV Vaccines Market?
  3. What are the technology trends and regulatory frameworks in the HIV Vaccines Market?
  4. What is the market share of the leading vendors in the HIV Vaccines Market?
  5. Which modes and strategic moves are suitable for entering the HIV Vaccines Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Frequently Asked Questions about the Global HIV Vaccines Market

What is the estimated value of the Global HIV Vaccines Market?

The Global HIV Vaccines Market was estimated to be valued at $943.11 Million in 2024.

What is the growth rate of the Global HIV Vaccines Market?

The growth rate of the Global HIV Vaccines Market is 39.6%, with an estimated value of $7011.84 Million by 2030.

What is the forecasted size of the Global HIV Vaccines Market?

The Global HIV Vaccines Market is estimated to be worth $7011.84 Million by 2030.

Who are the key companies in the Global HIV Vaccines Market?

Key companies in the Global HIV Vaccines Market include AlphaVax, Inc., Antigen Express, Inc., Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc. and GeoVax Labs, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. HIV Vaccines Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising investments for HIV vaccine production
5.1.1.2. Prevalence of HIV worldwide
5.1.1.3. Increasing awareness due to HIV prevention programs
5.1.2. Restraints
5.1.2.1. Issues related to HIV drug resistance
5.1.3. Opportunities
5.1.3.1. Rising affordability of HIV medicines
5.1.3.2. Increasing R&D activities for HIV vaccines clinical trials
5.1.4. Challenges
5.1.4.1. Limitations of commercialization of HIV vaccine
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. HIV Vaccines Market, by Antibodies
6.1. Introduction
6.2. Dicloxacillin
6.3. Fusidic Acid Ointment
6.4. Gentamicin Ointment
6.5. Mupirocin Ointment
7. HIV Vaccines Market, by Type
7.1. Introduction
7.2. Acute Paronychia
7.3. Candidal Paronychia
7.4. Chronic Paronychia
7.5. Pyogenic Paronychia
8. HIV Vaccines Market, by Category
8.1. Introduction
8.2. Preventive Vaccines
8.3. Therapeutic Vaccines
9. Americas HIV Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific HIV Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa HIV Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AlphaVax, Inc.
13.1.2. Antigen Express, Inc.
13.1.3. Argos Therapeutics, Inc.
13.1.4. Bionor Pharmaceuticals
13.1.5. Celldex Therapeutics, Inc.
13.1.6. Crucell N.V.
13.1.7. GeneCure LLC
13.1.8. Genetic Immunity, Inc.
13.1.9. GenVec, Inc.
13.1.10. GeoVax Labs, Inc.
13.1.11. GlaxoSmithKline plc
13.1.12. Immune Response BioPharma, Inc.
13.1.13. Inovio Pharmaceuticals, Inc.
13.1.14. Novartis AG
13.1.15. Oncolys Biopharma
13.1.16. Profectus Biosciences
13.1.17. Sanofi SA
13.1.18. TVAX Biomedical
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HIV VACCINES MARKET DYNAMICS
FIGURE 7. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
FIGURE 8. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HIV VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. HIV VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
FIGURE 12. HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 6. HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11. HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 16. HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 28. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 29. CANADA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 31. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 32. MEXICO HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 45. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 46. CHINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 48. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 49. INDIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 54. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 55. JAPAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 72. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 73. THAILAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 83. DENMARK HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 85. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 86. EGYPT HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 88. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 89. FINLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 91. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. FRANCE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 95. GERMANY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 100. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 101. ITALY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 109. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. NORWAY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 112. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 113. POLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 115. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. QATAR HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 127. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 128. SPAIN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 136. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. TURKEY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 145. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. HIV VACCINES MARKET LICENSE & PRICING

Companies Mentioned

  • AlphaVax, Inc.
  • Antigen Express, Inc.
  • Argos Therapeutics, Inc.
  • Bionor Pharmaceuticals
  • Celldex Therapeutics, Inc.
  • Crucell N.V.
  • GeneCure LLC
  • Genetic Immunity, Inc.
  • GenVec, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline plc
  • Immune Response BioPharma, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Novartis AG
  • Oncolys Biopharma
  • Profectus Biosciences
  • Sanofi SA
  • TVAX Biomedical

Methodology

Loading
LOADING...